Please login to the form below

Not currently logged in
Email:
Password:

neurodegenerative disorders

This page shows the latest neurodegenerative disorders news and features for those working in and with pharma, biotech and healthcare.

Axovant licenses another gene therapy as new strategy beds in

Axovant licenses another gene therapy as new strategy beds in

According to Wright, this ‘silence and replace’ approach is unique in gene therapy and “could be an elegant solution to tackling autosomal dominant genetic disorders” – in other words diseases caused even ... In neurology that includes a number

Latest news

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... Dr Mikael Dolsten, president of

  • Minoyrx Therapeutics appoints chief medical officer Minoyrx Therapeutics appoints chief medical officer

    He joins the Barcelona-based drug development company from Lupin Atlantis Holdings, where he oversaw its clinical strategy and implementation of studies in various therapeutic areas, including neurodegenerative disorders. ... Prior to this, Dr Meya was

  • Chase Pharmaceuticals appoints former Allergan president Chase Pharmaceuticals appoints former Allergan president

    As CEO, Ingram will focus on the direction of Chase Pharmaceuticals' development and commercialisation of improved treatments for neurodegenerative disorders, in particular its current work on symptomatic treatment of Alzheimer's

  • Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon

    phase III clinical programme targeting a genetically-defined Alzheimer's disease population, and execute on our long-term strategy to bring innovative therapies to patients with neurodegenerative disorders.”.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics